Therapeutics News and Research

RSS

Amorfix provides update on development of blood test for vCJD

Amorfix Life Sciences, a company focused on treatments and diagnostics for misfolded protein diseases, provides an update on the development of a blood test for vCJD, one of its six product development programs.

31 May 2010

BioTime offers 5 new human stem cell lines developed using ACTCellerate technology for research use

BioTime, Inc. announced today that on June 1, 2010 the Company will be offering for sale five new human stem cell lines for research use only. These cell lines were developed using BioTime's ACTCellerate™ technology. These highly purified, novel, and scalable cell lines are embryonic progenitors, meaning that they are intermediate between human embryonic stem cells and fully developed cells.

31 May 2010

HUYA Bioscience International forms strategic partnership with School of Chinese Materia Medica of BUCM

HUYA Bioscience International, a leader in globalizing China's biopharmaceutical innovation, today announced a strategic partnership with the School of Chinese Materia Medica of the Beijing University of Chinese Medicine (BUCM). As one of a series of collaborations that HUYA has established with China's leading research and development institutions, the agreement demonstrates HUYA's visionary commitment to enabling and accelerating the global development and commercialization of novel biopharmaceutical products originating in China.

29 May 2010

Study demonstrates protection against Ebola infection in nonhuman primates using RNAi

Scientists using tiny particles of genetic material to interfere in the replication process of the deadly Ebola virus have successfully prevented monkeys exposed to that virus from dying of hemorrhagic fever. The proof-of-concept study, published in this week's issue of The Lancet, suggests that such protection also should be possible in humans.

29 May 2010

New, non-controversial source of stem cells can form heart muscle cells, repair heart damage

A new and non-controversial source of stem cells can form heart muscle cells and help repair heart damage, according to results of preliminary lab tests reported in Circulation Research: Journal of the American Heart Association.

29 May 2010

Amorfix, Aragen Bioscience collaborate to develop high-affinity monoclonal antibodies against targets for cancer

Amorfix Life Sciences and Aragen Bioscience, Inc. announced today that they have entered into an agreement to develop high-affinity monoclonal antibodies against a number of targets for cancer. Using its proprietary ProMIS(TM) computational platform discovery technology, Amorfix has identified several disease specific epitopes ("DSEs") on misfolded Fas receptor. Aragen will use those DSEs to generate highly specific monoclonal antibodies ("mAbs").

28 May 2010

Advocates urge Congress to reauthorize C.W. Bill Young Cell Transplantation Program and NCBI

More than 60 adult donors, transplant recipients, family members and medical professionals from 25 states met with lawmakers and staff on Capitol Hill today to urge Congress for increased federal funding to grow and diversify the national registry of adult donors and publicly available cord blood units as part of the C.W. Bill Young Transplantation Program and the National Cord Blood Inventory.

28 May 2010

CrystalGenomics to merge with BexPharm

CrystalGenomics, Inc., a leading biopharmaceutical company developing novel small molecule therapeutics announced today that it will merge with BexPharm, a specialty pharmaceutical company that imports and distributes foreign market approved drugs in Korea.

28 May 2010

NeoStem to present adult stem cell technologies at Stem Cell Investor & Executive Networking Conference

NeoStem, Inc., an international biopharmaceutical company with operations in the U.S. and China, announced that the Company has been invited to present its adult stem cell technologies at the Stem Cell Investor & Executive Networking Conference Event (SCIENCE) in New York City on June 1, 2010. SCIENCE is designed to bring together investors with industry executives, visionary researchers and clinicians and other stakeholders to highlight opportunities and discuss advances in the stem cell field.

28 May 2010

Regulus Therapeutics obtains rights to intellectual property covering methods for modulating microRNA-21

Regulus Therapeutics Inc. announced today that it has obtained exclusive rights from the University of Wuerzburg to intellectual property covering methods for modulating microRNA-21. Regulus scientists and collaborators have shown that microRNA-21, (miR-21), is dysregulated in mouse models of cardiac disease and fibrosis, and that antagonizing miR-21 with therapeutic oligonucleotides targeting miR-21 inhibits fibrosis and attenuates cardiac function in such models. Regulus is currently developing a microRNA therapeutic targeting miR-21 as an anti-fibrotic therapy.

28 May 2010

The Wistar Institute Melanoma Research Center launched to develop new therapies for melanoma

In an effort to meet the rising rates of melanoma head-on, The Wistar Institute today announced the creation of The Wistar Institute Melanoma Research Center. The Center brings together scientists, physicians, the life sciences industry, and melanoma advocates in saving lives by advancing new and better therapies for this deadly disease.

28 May 2010

OHSU partners with UO, Harvard to expedite research into compounds that may prevent Fanconi anemia

Oregon Health & Science University is partnering with the University of Oregon and Harvard Medical School to expedite basic science research into new and existing drugs and compounds that may prevent the complications associated with Fanconi anemia, an inherited condition that can lead to bone marrow failure and cancer.

28 May 2010

Research finding may offer future alternative to antibiotics

A team of scientists from government, academia and private industry has developed a novel treatment that protects mice from infection with the bacterium that causes tularemia, a highly infectious disease of rodents, sometimes transmitted to people, and also known as rabbit fever. In additional experiments with human immune cells, the treatment also demonstrated protection against three other types of disease-causing bacteria that, like the tularemia bacteria, occur naturally, can be highly virulent, and are considered possible agents of bioterrorism.

28 May 2010

NOXXON Pharma closes €33 million Series D round of financing

NOXXON Pharma AG, a company focused on the development of mirror image oligonucleotide therapeutics called Spiegelmers®, announced today the successful closing of a €33 million Series D round of financing. The round was led by new investor, NGN Capital, and joined by existing investors TVM Capital, Sofinnova Partners, Edmond de Rothschild Investment Partners, Seventure Partners, VC Fonds Technologie Berlin GmbH, Dow Venture Capital, FCP OP MEDICAL BioHealth-Trends, IBG Beteiligungsgesellschaft Sachsen-Anhalt mbH, the Dieckell Group, and others.

27 May 2010

YM BioSciences initiates enrollment in nimotuzumab trial in brain metastases from NSCLC

YM BioSciences Inc., today announced that the first US patient has been enrolled in its randomized, double-blind trial evaluating nimotuzumab in patients with brain metastases from NSCLC at the Florida Cancer Institute - New Hope. This trial initiation follows recent clearance from the US FDA announced on January 26, 2010 allowing the Company to enroll patients at US clinical sites for two of its international and ongoing randomized, double-blind Phase II trials of nimotuzumab.

27 May 2010

Space Shuttle Atlantis returns from International Space Station with tenth scientific payload for Astrogenetix

Space Shuttle Atlantis returned from the International Space Station (ISS) landing at the Kennedy Space Center this morning with the tenth scientific payload for Astrogenetix, a commercial biotech company based out of Austin, Texas. Astrogenetix is conducting research on methicillin-resistant Staphylococcus aureus (MRSA) as part of the ISS National Laboratory Pathfinder Vaccine (NLP-V) missions.

27 May 2010

Abbott Biotech Ventures invests in Alvine Pharmaceuticals

Alvine Pharmaceuticals, Inc., a privately held clinical stage biopharmaceutical company focused on developing and commercializing therapeutics for autoimmune/inflammatory diseases, today announced that Abbott Biotech Ventures Inc., has joined Alvine's current investors: Interwest Partners, Panorama Capital, Prospect Venture Partners, Sofinnova Ventures, Black River Asset Management and Flagship Ventures in the company's Series A Extension financing. The terms of the investment were not disclosed.

27 May 2010

PBI awarded contract to provide essential laboratory data for Phase I cardiovascular trial

Pacific Biomarkers, Inc. has been awarded a contract by a leading multinational pharmaceutical company to provide essential laboratory data for an adaptive Phase I cardiovascular trial. This study is part of a major drug-development program to evaluate an innovative new treatment to reduce recurrent cardiovascular events associated with acute coronary syndrome.

27 May 2010

TESARO secures $60 million in start-up funding to acquire, develop and commercialize cancer therapeutics

TESARO, Inc., an oncology-focused biopharmaceutical company, today announced that it has secured $60 million in start-up funding to acquire, develop and commercialize cancer therapeutics and supportive care products. Participants in a $20 million Series A financing included New Enterprise Associates (NEA) and TESARO management; additionally, NEA has reserved $40 million to support company growth.

27 May 2010

Logical Therapeutics closes $16.9 million Series C equity financing round

Logical Therapeutics, Inc., a private, clinical stage biopharmaceutical company, announced today it had closed on a $16.9 million Series C equity financing. The round was led by existing investor SV Life Sciences, and included Burrill & Company, Novo A/S and Novitas Capital.

27 May 2010

Therapeutics News and Research

Amorfix provides update on development of blood test for vCJD

BioTime offers 5 new human stem cell lines developed using ACTCellerate technology for research use

HUYA Bioscience International forms strategic partnership with School of Chinese Materia Medica of BUCM

Study demonstrates protection against Ebola infection in nonhuman primates using RNAi

New, non-controversial source of stem cells can form heart muscle cells, repair heart damage

Amorfix, Aragen Bioscience collaborate to develop high-affinity monoclonal antibodies against targets for cancer

Advocates urge Congress to reauthorize C.W. Bill Young Cell Transplantation Program and NCBI

CrystalGenomics to merge with BexPharm

NeoStem to present adult stem cell technologies at Stem Cell Investor & Executive Networking Conference

Regulus Therapeutics obtains rights to intellectual property covering methods for modulating microRNA-21

The Wistar Institute Melanoma Research Center launched to develop new therapies for melanoma

OHSU partners with UO, Harvard to expedite research into compounds that may prevent Fanconi anemia

Research finding may offer future alternative to antibiotics

NOXXON Pharma closes €33 million Series D round of financing

YM BioSciences initiates enrollment in nimotuzumab trial in brain metastases from NSCLC

Space Shuttle Atlantis returns from International Space Station with tenth scientific payload for Astrogenetix

Abbott Biotech Ventures invests in Alvine Pharmaceuticals

PBI awarded contract to provide essential laboratory data for Phase I cardiovascular trial

TESARO secures $60 million in start-up funding to acquire, develop and commercialize cancer therapeutics

Logical Therapeutics closes $16.9 million Series C equity financing round

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News